{"id":"NCT01159600","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes","officialTitle":"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2012-02","completion":null,"firstPosted":"2010-07-09","resultsPosted":"2014-06-17","lastUpdate":"2014-06-17"},"enrollment":1504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Placebo identical to BI 10773 high dose","otherNames":[]},{"type":"DRUG","name":"Placebo identical to BI 10773 low dose","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo identical to BI 10773 low dose","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo identical to BI 10773 high dose","otherNames":[]}],"arms":[{"label":"BI 10773 Arm 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"BI 10773 open-label","type":"EXPERIMENTAL"},{"label":"BI 10773 Arm 1","type":"EXPERIMENTAL"}],"summary":"The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.","primaryOutcome":{"measure":"HbA1c Change From Baseline","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Met: Placebo","deltaMin":-0.13,"sd":0.05},{"arm":"Met: Empa 10mg","deltaMin":-0.7,"sd":0.05},{"arm":"Met: Empa 25mg","deltaMin":-0.77,"sd":0.05},{"arm":"Met: Empa 25mg Open Label","deltaMin":-2.78,"sd":0.21},{"arm":"Met+SU: Placebo","deltaMin":-0.17,"sd":0.05},{"arm":"Met+SU: Empa 10mg","deltaMin":-0.82,"sd":0.05},{"arm":"Met+SU: Empa 25mg","deltaMin":-0.77,"sd":0.05},{"arm":"Met+SU: Empa 25mg Open Label","deltaMin":-2.53,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG004 vs OG005","p":"<0.0001"},{"comp":"OG004 vs OG006","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":148,"countries":["United States","Canada","China","France","Germany","India","Mexico","Slovakia","Slovenia","South Korea","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["38770818","35472672","33084149","27316632","23963895"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":206},"commonTop":["Nasopharyngitis","Hypoglycaemia","Urinary tract infection","Hyperglycaemia","Upper respiratory tract infections"]}}